Last reviewed · How we verify

Standard of care_1

Ain Shams University · Phase 3 active Small molecule

Standard of care_1 is a Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Standard of care. Also known as: Plaquenil.

This drug is a standard of care in phase 3 clinical trials.

This drug is a standard of care in phase 3 clinical trials. Used for Standard of care.

At a glance

Generic nameStandard of care_1
Also known asPlaquenil
SponsorAin Shams University
ModalitySmall molecule
PhasePhase 3

Mechanism of action

The exact mechanism of action is not specified.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of care_1

What is Standard of care_1?

Standard of care_1 is a Small molecule drug developed by Ain Shams University, indicated for Standard of care.

How does Standard of care_1 work?

This drug is a standard of care in phase 3 clinical trials.

What is Standard of care_1 used for?

Standard of care_1 is indicated for Standard of care.

Who makes Standard of care_1?

Standard of care_1 is developed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

Is Standard of care_1 also known as anything else?

Standard of care_1 is also known as Plaquenil.

What development phase is Standard of care_1 in?

Standard of care_1 is in Phase 3.

Related